

Company Number: 709747

AIM Pharma Ltd
Abridged Unaudited Financial Statements
for the financial year ended 10 June 2025

AIM Pharma Ltd
CONTENTS

	Page
Directors and Other Information	3
Statement of Total Recognised Gains and Losses	4
Balance Sheet	5
Notes to the Financial Statements	6 - 9

AIM Pharma Ltd
DIRECTORS AND OTHER INFORMATION

Directors	Rubina Rehan Mohammed Mirza
Company Secretary	Mohammed Mirza
Company Number	709747
Registered Office and Business Address	Unit 3, Corner of Main Street -Quay Road Clarecastle Clare V95 V588
Accountants	Belgrave Accountants & Tax Consultants Ltd Chartered Accountants Unit 1 Ballycasey Business Park Shannon Clare V14 CK22 Ireland

AIM Pharma Ltd**STATEMENT OF TOTAL RECOGNISED GAINS AND LOSSES**

for the financial year ended 10 June 2025

	2025 €	2024 €
Loss after taxation	(1,544)	(13,350)
Total recognised losses for the financial year	<u>(1,544)</u>	<u>(13,350)</u>
Total recognised losses since last annual report	<u>(1,544)</u>	<u>(13,350)</u>

Note of historical cost profits and losses

The difference between the results as disclosed in the Profit and Loss Account and the result on an unmodified historical cost basis is not material.

AIM Pharma Ltd

BALANCE SHEET

as at 10 June 2025

	Notes	2025 €	2024 €
Fixed Assets			
Tangible assets	6	148	172
Current Assets			
Debtors	7	1,907	1,170
Cash at bank and in hand		10,234	24,115
		12,141	25,285
Creditors: amounts falling due within one year	8	(1,520)	(13,144)
Net Current Assets		10,621	12,141
Total Assets less Current Liabilities		10,769	12,313
Capital and Reserves			
Called up share capital presented as equity	10	100	100
Retained earnings	11	10,669	12,213
Shareholders' Funds		10,769	12,313

We as Directors of AIM Pharma Ltd, state that -

(a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,

(b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,

(c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),

(d) we acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,

(e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the micro companies' regime.

Approved by the board on 27 January 2026 and signed on its behalf by:

Mohammed Mirza
Director

Rubina Rehan
Director

AIM Pharma Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 10 June 2025

1. General Information

AIM Pharma Ltd is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 709747. The registered office of the company is Unit 3, Corner of Main Street -Quay Road, Clarecastle, Clare, V95 V588 which is also the principal place of business of the company. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. Summary of Significant Accounting Policies

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company's financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 10 June 2025 have been prepared on the going concern basis and in accordance with FRS 105 "The Financial Reporting Standard for Micro-Entities applicable in the UK and Republic of Ireland" (FRS 105).

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 105 "The Financial Reporting Standard applicable to the Micro-Entities Regime" issued by the Financial Reporting Council.

The company qualifies as a micro company as defined by section 280D of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Micro Companies Regime' in accordance with section 280E of the Companies Act 2014 and FRS 105.

Accounting Convention

The financial statements are prepared under the historical cost convention.

Turnover

Turnover comprises the invoice value of goods supplied by the company, exclusive of trade discounts and value added tax.

Tangible assets and depreciation

Tangible assets are stated at cost or at valuation, less accumulated depreciation. The charge to depreciation is calculated to write off the original cost or valuation of tangible assets, less their estimated residual value, over their expected useful lives as follows:

Fixtures, fittings and equipment	-	12.5% Straight line
----------------------------------	---	---------------------

The carrying values of tangible fixed assets are reviewed annually for impairment in periods if events or changes in circumstances indicate the carrying value may not be recoverable.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

Employee benefits

The company operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the company in an independently administered fund. The company also operates a defined benefit pension scheme for its employees providing benefits based on final pensionable pay. The assets of this scheme are also held separately from those of the company, being invested with pension fund managers.

AIM Pharma Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 10 June 2025

Taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the balance sheet date. Transactions, during the financial year, which are denominated in foreign currencies are translated at the rates of exchange ruling at the date of the transaction. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. Turnover

The whole of the company's turnover is attributable to its market in the Republic of Ireland and is derived from the principal activity of

4. Operating loss	2025	2024
	€	€
Operating loss is stated after charging:		
Depreciation of tangible assets	24	24

5. Employees

The average monthly number of employees, including directors, during the financial year was 0, (2024 - 0).

6. Tangible assets

	Fixtures, fittings and equipment	Total
	€	€
Cost		
At 11 June 2024	196	196
At 10 June 2025	196	196
Depreciation		
At 11 June 2024	24	24
Charge for the financial year	24	24
At 10 June 2025	48	48
Net book value		
At 10 June 2025	148	148
At 10 June 2024	172	172

7. Debtors	2025	2024
	€	€
Taxation	1,907	1,170

AIM Pharma Ltd
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
for the financial year ended 10 June 2025

8. Creditors		2025	2024
Amounts falling due within one year		€	€
Taxation		-	10,824
Accruals		1,520	2,320
		1,520	13,144

9. Taxation		2025	2024
		€	€
Debtors:			
VAT		-	1,170
Corporation tax		1,907	-
		1,907	1,170
Creditors:			
Corporation tax		-	10,824

10. Share capital		2025	2024
		€	€
Description	Number of shares	Value of units	
Authorised			
€1 Ordinary	100,000	€1.00 each	100,000
			100,000
Allotted, called up and fully paid			
€1 Ordinary	100	€1.00 each	100
			100

The directors' and the secretary's interests in the shares of the company are as follows:-

		Number Held	
Name	Class of Shares	At	
		10/06/25	11/06/24
Mohammed Mirza	€1 Ordinary	100	100

11. Profit and loss account		2025	2024
		€	€
At 11 June 2024		12,213	25,563
Loss for the financial year		(1,544)	(13,350)
At 10 June 2025		10,669	12,213

12. Capital commitments

The company had no material capital commitments at the financial year-ended 10 June 2025.

13. Post-Balance Sheet Events

There have been no significant events affecting the company since the financial year-end.

AIM Pharma Ltd

NOTES TO THE ABRIDGED FINANCIAL STATEMENTS

for the financial year ended 10 June 2025

14. Approval of financial statements

The financial statements were approved and authorised for issue by the board of directors on 27 January 2026.